Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal HR-positive HER2-negative advanced breast cancer after aromatase inhibitor treatment
2011-005524-17Phase 3Terminated
- Sponsor
- Novartis
- Start
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Buparlisib + fulvestrant with Placebo + fulvestrant (2 arms). Primary endpoint: Progression-free survival. Started Jun 2012; status: terminated.
02
Drugs
buparlisibfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2011-005524-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005524-17.